Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, comments on the updated results from the SIMPLIFY-1 (NCT01969838), SIMPLIFY-2 (NCT02101268), and MOMENTUM (NCT04173494) studies evaluating momelotinib in patients with myelofibrosis (MF). Data from these three studies reported a good durability of response, a benefit in survival, and a consistent safety profile for momelotinib, without any unexpected adverse events. In addition, it was shown that it is feasible to switch from danazol or ruxolitinib to momelotinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
